Payment overview · 2025
General Payments
$428.49
10 reported records · 4 companies
Healthcare provider profile · identity verified
Robert Ashley, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SANTA MONICA, CA · NPI 1780628487
Verified facts
What the public records show
CMS Open Payments records show Robert Ashley, MD received $428.49 in general payments during 2025 across 10 reported records.
Supernus Pharmaceuticals, Inc. accounted for 39.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Jardiance by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Xarelto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $169.98 | 39.7% | 7 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $123.79 | 28.9% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $115.87 | 27.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.85 | 4.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $409.64 | 9 |
| Education | $18.85 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $169.98 | 7 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $123.79 | 1 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $115.87 | 1 | 2025 |
Source payment records
|
|||||
| INVEGA TRINZA Normalized: invega trinza |
Drug | Janssen Pharmaceuticals, Inc | $115.87 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 337 | 89 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 326 | 91 |
| Amlodipine Besylate | Amlodipine Besylate | 323 | 93 |
| Fluticasone Propionate | Fluticasone Propionate | 243 | 112 |
| Levothyroxine Sodium | Levothyroxine Sodium | 221 | 56 |
| Losartan Potassium | Losartan Potassium | 164 | 46 |
| Pantoprazole Sodium | Pantoprazole Sodium | 142 | 36 |
| Lisinopril | Lisinopril | 128 | 36 |
| Omeprazole | Omeprazole | 125 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 119 | 38 |
| Zolpidem Tartrate | Zolpidem Tartrate | 115 | 28 |
| Gabapentin | Gabapentin | 106 | 37 |
| Trazodone Hcl | Trazodone Hcl | 102 | 33 |
| Metformin Hcl Er | Metformin Hcl | 99 | 30 |
| Mirtazapine | Mirtazapine | 96 | 17 |
| Montelukast Sodium | Montelukast Sodium | 96 | 32 |
| Famotidine | Famotidine | 88 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 87 | 22 |
| Alprazolam | Alprazolam | 84 | 29 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 83 | 16 |
| Buspirone Hcl | Buspirone Hcl | 80 | 23 |
| Azelastine Hcl | Azelastine Hcl | 79 | 42 |
| Allopurinol | Allopurinol | 78 | 16 |
| Bupropion Xl | Bupropion Hcl | 70 | 21 |
| Meloxicam | Meloxicam | 65 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 65 | 20 |
| Ozempic | Semaglutide | 63 | suppressed |
| Simvastatin | Simvastatin | 62 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 61 | 14 |
| Eliquis | Apixaban | 58 | 16 |
| Atenolol | Atenolol | 57 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 56 | 36 |
| Valacyclovir | Valacyclovir Hcl | 56 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 55 | 17 |
| Celecoxib | Celecoxib | 53 | 37 |
| Lorazepam | Lorazepam | 52 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 52 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 50 | 16 |
| Eszopiclone | Eszopiclone | 50 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 50 | 18 |
| Alendronate Sodium | Alendronate Sodium | 47 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | 14 |
| Metformin Hcl | Metformin Hcl | 44 | 14 |
| Verapamil Er | Verapamil Hcl | 44 | 11 |
| Benazepril Hcl | Benazepril Hcl | 43 | 13 |
| Clonazepam | Clonazepam | 42 | suppressed |
| Finasteride | Finasteride | 40 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 37 | 12 |
| Azithromycin | Azithromycin | 36 | 36 |
| Ketoconazole | Ketoconazole | 36 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 36 | 11 |
| Furosemide | Furosemide | 35 | 12 |
| Januvia | Sitagliptin Phosphate | 35 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 34 | 15 |
| Pregabalin | Pregabalin | 34 | suppressed |
| Prednisone | Prednisone | 33 | 23 |
| Terazosin Hcl | Terazosin Hcl | 33 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 32 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Ezetimibe | Ezetimibe | 31 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 31 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | 11 |
| Sertraline Hcl | Sertraline Hcl | 29 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 28 | 28 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Valsartan | Valsartan | 27 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Minoxidil | Minoxidil | 26 | 11 |
| Synthroid | Levothyroxine Sodium | 26 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 25 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Carvedilol | Carvedilol | 24 | suppressed |
| Jardiance | Empagliflozin | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | 13 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 18 |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | 11 |
| Estradiol | Estradiol | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Cephalexin | Cephalexin | 19 | 15 |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Potassium Chloride | Potassium Chloride | 19 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 16 |
| Folic Acid | Folic Acid | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 16 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | suppressed |
| Belsomra | Suvorexant | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Progesterone | Progesterone, Micronized | 14 | suppressed |
| Prolia | Denosumab | 14 | suppressed |
| Seroquel | Quetiapine Fumarate | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | 13 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $428.49 · 10 records | Supernus Pharmaceuticals, Inc. | FANAPT, INVEGA SUSTENNA, INVEGA TRINZA, JARDIANCE, Qelbree | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error